Left ventricular hypertrophy reversal and prevention of diabetes: two birds with one stone?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease.Journal of the American Society of Nephrology : JASN · 2011
   Trial
2. The Diabetic Cardiorenal Nexus.International journal of molecular sciences · 2022
   Review
3. Cardiovascular changes during chronic hypertensive states.Pediatric nephrology (Berlin, Germany) · 2014
   Review
4. N-terminal pro-atrial natriuretic peptide reflects cardiac remodelling in stage 1 hypertension.Journal of human hypertension · 2011
   Article
5. The electrocardiogram is an unreliable method of identifying left ventricular hypertrophy in stable, treated angina patients.Journal of human hypertension · 2008
   Article
6. Prevention of diabetes and left ventricular hypertrophy with AT1 receptor blockade for hypertension.Current hypertension reports · 2008
   Article

Corrections and comments

• Comment on
  In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.2007

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as